---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-044747"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T16:13:40.410953+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Virpax prices $2.25M public offering of common stock and warrants

## Summary
- Gross proceeds of ~$2.25M from offering of 1,666,667 shares/equivalents plus Series A-1 and A-2 warrants.
- Series A-1 warrants exercisable at $1.35/share, expire in 5 years; Series A-2 at $1.35/share, expire in 18 months.
- Proceeds to be used for working capital, general corporate purposes, and possibly settling a portion of an obligation.
- After closing, 2,741,600 shares of common stock outstanding.
- A.G.P./Alliance Global Partners acted as sole placement agent.

## SEC filing metadata
- accession: 0001213900-24-044747
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/0001213900-24-044747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/ea0206438-8k_virpax.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-044747
- JSON: https://secwatch.observer/filing/0001213900-24-044747.json
- Plain text: https://secwatch.observer/filing/0001213900-24-044747.txt

## Key facts
- Material Agreements
  Virpax Pharmaceuticals, Inc. entered into Purchase Agreement with certain investors (effective 2024-05-14).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Effective: 2024-05-14
  source text: In connection with the Offering, on May 14, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/0001213900-24-044747-index.htm
- Material Agreements
  Virpax Pharmaceuticals, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2024-05-14).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: A.G.P./Alliance Global Partners
  - Effective: 2024-05-14
  source text: Also, in connection with the Offering, on May 14, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/0001213900-24-044747-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.